Journal Mobile Options
Table of Contents
Vol. 66, No. 5, 2006
Issue release date: October 2006
Horm Res 2006;66:236–239

Correlation between Serum Osteoprotegerin and Biomarkers of Bone Metabolism during Anti-Thyroid Treatment in Patients with Graves’ Disease

Mochizuki Y. · Banba N. · Hattori Y. · Monden T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Bone turnover is increased in favor of resorption in hyperthyroid patients. We aimed to examine whether osteoprotegerin (OPG), which has an inhibitory effect on osteoclasts, is correlated with any biomarkers for bone turnover in Graves’ disease. Twenty-one patients with Graves’ disease were examined in this study, before and after treatment. Briefly, OPG, calcium, phosphorus, PTH, free T3, free T4, TSH, TSH receptor antibody and TSH-stimulating antibody were measured. Elevated serum OPG levels were decreased in accordance with anti-thyroid treatment. This change of OPG level was associated with thyroid hormone free T4 (r = 0.175, p = 0.038) but not with free T3 (r = 0.164, p = 0.052) and TSH (r = 0.046, p = 0.59). Additionally, there was a negative correlation between OPG and PTH (r = –0.37, p = 0.0001). In stepwise regression analysis, the change in serum OPG levels during anti-thyroid treatment was significantly and independently associated with PTH (F ratio = 24.4, p < 0.0001). Our findings suggest that OPG may prevent excessive bone loss in the hyperthyroid state in accordance with the change of biomarkers for bone turnover.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319.
  2. Khosla S: The OPG/RANKL/RANK system. Endocrinology 2001;142:5050–5055.
  3. Langdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 1996;6:161–168.
  4. Lanfdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, calcium homeostasis, and body composition in surgically and radioiodine-treated former hyperthyroid patients. Thyroid 1996;6:169–175.

    External Resources

  5. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000;85:4157–4161.
  6. Siddiqi A, Burrin JM, Noonan K, James I, Wood DF, Price CP, Monson JP: A longitudinal study of markers of bone turnover in Graves’ disease and their value in predicting bone mineral density. J Clin Endocrinol Metab 1997;82:753–759.
  7. Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C: High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004;35:785–791.
  8. Gao P, Scheibel S, D’amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL: Development of novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605–614.
  9. Varga F, Spitzer S, Klaushofer K: Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25 D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 2004;74:382–387.
  10. Abe E, Marinas RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 2003;115:151–162.
  11. Kisakol G, Kaya A, Gonen S, Tunc R: Bone and calcium metabolism in subclinical autoimmune hyperthyroidism and hypothyroidism. Endocr J 2003;50:657–661.
  12. Pantazi H, Papapetrou PD: Change in parameters of bone and mineral metabolism during therapy for hyperthyroidim. J Clin Endocrinol Metab 2000;85:1099–1106.
  13. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD: Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162–3165.
  14. Lee S-K, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552–3561.
  15. Gonnelli S, Montagnani A, Caffarelli C, Cadirni A, Campagna MS, Franci MB, Lucani B, Gaggiotti E, Nuti R: Osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005;28:534–539.
  16. Nagasaki T, Inaba M, Jono S, Hiura Y, Tahara H, Shirakawa K, Onoda N, Ishikawa T, Ishimura E, Nishizawa Y: Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 2005;152:347–353.
  17. Guang-da X, Hui-ling S, Zhi-song C, Lin-shuang Z: Change in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 2005;90:5765–5768.
  18. Cappola AR, Ladenson PW: Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003;88:2438–2444.
  19. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR: Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 2004;89:3764–3768.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00